BEAM Beam Therapeutics

Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022

Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022

Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company has ranked No. 4 on the Boston Globe’s 2022 Top Places to Work in the “Large Companies” category, marking its fourth consecutive year as an honoree.

The Boston Globe’s , which will be featured in the print edition of Sunday’s paper, recognizes the most admired workplaces in the state, voted on by the people who know them best – their employees. The survey measures employee opinions about their company's leadership, appreciation, benefits and more. The winners are divided into four categories based on the number of employees: small (50-99); medium (100-249); large (250-999); and largest (1,000 or more). More than 94,000 employees at 381 companies completed surveys this year—a record high.

“At Beam, our vision is to provide life-long cures for patients suffering from serious diseases, and the ‘Beam Team’ is not only committed to making breakthroughs happen; they are committed to making Beam an exciting place to work, motivating colleagues and building a strong company culture in the process,” Susan O’Connor, chief human resource officer at Beam. “We are proud to be named, for the fourth year in a row, to this prestigious list of companies is Massachusetts who are committed to their missions, and importantly, each other.”

As an employer of choice, Beam is committed to fostering a culture that encourages employees to engage with colleagues. The company’s culture team frequently hosts programs on wellness, community engagement, diversity and inclusion, and team building to inspire, educate and care for employees. Events like Beam’s annual summer party, various walks and events in support of patient advocacy groups (including Light the Night and Walk with the Stars) and its “Balance @ Beam” wellness program supporting mental and financial health, demonstrate the company’s commitment to creating a culture that allows employees to thrive. Beam’s extensive benefits package includes programs like its "Take It as You Need It" paid time off policy, a five-week paid sabbatical after five years with an additional $5,000 stipend, medical benefits, a health and fitness reimbursement, 401k retirement plan, commuter reimbursement, family-forming benefits, an employee referral program and student loan refinancing.

In addition to its recognition as one of the Top Places to Work, Beam was named to the 2022 Best Places to Work list by the Boston Business Journal. For more information on careers at Beam, please visit .

About Beam Therapeutics

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contacts:

Investors:

Chelcie Lister

THRUST Strategic Communications

Media:

Dan Budwick

1AB



EN
02/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Beam Therapeutics

Wedbush Research
  • Wedbush Research
 PRESS RELEASE

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial R...

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated L...

 PRESS RELEASE

Beam Therapeutics Announces $500 Million Strategic Financing Facility ...

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street $100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD) CAMBRIGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM) today announced that it has entered into a strategic financing agreement with Sixth Street for substantial, long-term, non-dilutive capital to fund the potential launch of ristoglogen...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year...

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET.The live webcast will be available in the investor section of the company'...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch